CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Prone positioningWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug1263 Isoprinosine Wiki 0.58
drug1334 Levamisole Wiki 0.58
drug2629 Vazegepant (BHV-3500) Wiki 0.58
drug1917 Prone Wiki 0.58
drug1336 Levamisole and Isoprinosine Wiki 0.58
drug2612 Usual Care Wiki 0.26
drug1822 Placebo Wiki 0.03

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D000860 Hypoxia NIH 0.13
D018352 Coronavirus Infections NIH 0.07
D013577 Syndrome NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012418 Hypoxemia HPO 0.13

There are 3 clinical trials

Clinical Trials

1 Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)

The prone position consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day and could help spontaneous ventilate the patient.

NCT04344106 Coronavirus Infection Oxygen Deficiency Procedure: Prone positioning
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: PaO2 improvement of more than 20% after one hour in prone position in spontaneously breathing non intubated COVID-19 patients.

Measure: Proportion of "responder" patients to prone position

Time: 1 hour

Secondary Outcomes

Description: PaO2 improvement of more than 20% at 6 to 12 hours from return to supine position.

Measure: proportion of "persistent responders" patients after prone position

Time: 1 day

Description: PaO2 at 1 hour from the start of prone position and at 6 to 12 hours afterreturn to supine position.

Measure: Evolution of PaO2

Time: 1 day

Description: Look for an association between the time spent in Prone positione and persistent responder or not;

Measure: Duration of prone positioning and PaO2 evolution

Time: 2 days

Description: proportion of patients improving their arterial saturation within 1 hour of Prone Position

Measure: Evolution of Spo2

Time: 1 hour

Description: evolution of the EVA scores for dyspnea at 1 hour from the start of the Prone Position and at 6 hours after the end of the Prone Position

Measure: EVA Dyspnea

Time: 1 day

Description: proportion of patients intolerant to prone position (Prone Position <1h);

Measure: Intolerance to prone positioning

Time: 1 day

Description: proportion of patients who can maintain prone position for more than 3 h.

Measure: Tolerance to prone positioning

Time: 1 day

2 The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome

The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity. The purpose of the study is to quantify with the electrical impedance tomography (EIT) the changes in the ventilation and aeration in the dorsal regions of the lung when the patient is placed in prone position.

NCT04359407 Severe Acute Respiratory Syndrome Coronavirus 2 Electric Impedance Prone Positioning Other: Prone positioning
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Syndrome

Primary Outcomes

Description: Change in the ratio of tidal electrical impedance variation in the dorsal and total lung areas

Measure: Tidal electrical Impedance

Time: One hour before turning to prone or supine positioning

Secondary Outcomes

Description: Changes in intrapulmonary shunt fraction

Measure: Intrapulmonary shunt

Time: One hour before turning to prone or supine positioning

Description: Changes in the phase three slope of the volumetric capnogram

Measure: Volumetric capnography

Time: One hour before turning to prone or supine positioning

3 Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE]

COVID-PRONE is a multicenter, pragmatic, single-blind, 2-arm, parallel, randomized controlled trial seeking to compare the pre-emptive prone positioning (i.e. encouraging patients to adopt a prone position before they require mechanical ventilation) to the control arm of standard care alone. Randomization will be stratified by site.

NCT04383613 Covid-19 ARDS Other: Prone positioning

Primary Outcomes

Measure: Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more

Time: From date of randomization until the date of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, need for FiO2 of 60% or more, or date of hospital discharge, whichever came first, assessed up to 4 weeks

Secondary Outcomes

Measure: Length of hospitalization

Time: Up to 4 weeks

Measure: Adverse events of prone positioning (i.e., venous thromboembolism, pneumonia)

Time: Up to 7 days [or until hospital discharge]

Measure: In-hospital all-cause mortality

Time: From date of randomization until the date of in-hospital all-cause mortality or date of hospital discharge, whichever came first, assessed up to 4 weeks

Measure: Invasive or non-invasive mechanical ventilation

Time: From date of randomization until the date of invasive or non-invasive mechanical ventilation, or date of hospital discharge, whichever came first, assessed up to 4 weeks

Measure: Need for FiO2 of 60% or more

Time: From date of randomization until the date of need for FiO2 of 60% or more, or date of hospital discharge, whichever came first, assessed up to 4 weeks

Measure: Ventilator-free days (i.e., the number of days in hospital the patient was not on a ventilator)

Time: Up to 8 weeks

Measure: Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more assessed at 30 days, 90 days and 1 year

Time: 30 days, 90 days and 1 year after randomization

Measure: Time spent in prone positioning among patients achieving the composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more

Time: Up to 7 days

Other Outcomes

Description: I) The ratio between the patient's oxygen saturation and the amount of oxygen they're inspiring, II) Sustained (i.e., more than 5 minutes) drop in oxygen saturation less than 88% in the prone position on the same oxygen therapy required to maintain a saturation of >92% in the supine position.

Measure: Feasibility outcome: Change in oxygen saturation before and after prone positioning (to be measured for 72 hours beginning at the time of randomization), which will be calculated as:

Time: 72 hours

Description: Rate of serious adverse events as identified through routine care by the patient's attending physician (e.g., venous thromboembolism, pneumonia) or through objective testing (i.e., death, transfer to the intensive care unit). Notably, bacterial pneumonia will be pragmatically defined through the combination of a chest x-ray report identifying evidence of pneumonia and the receipt of antibiotics known to treat pneumonia

Measure: Feasibility outcome: Rate or serious adverse events

Time: Up to 7 days

Description: The patients will be called each day for the first 72 hours by the research assistant/coordinator and will be asked to provide an estimate of the number of hours spent in prone position in the previous 24 hours.

Measure: Feasibility outcome: Adherence to prone positioning

Time: Up to 72 hours

Related HPO nodes (Using clinical trials)

HP:0012418: Hypoxemia
Genes 14
GATA6 GDNF HBB SLC35A1 ASCL1 ZFPM2 EDN3 HBB RET PHOX2B CSF2RA FBN1 FGFR3 CSF2RB
Protein Mutations 2
P317R R200W
SNP 0